Subtype
Male Reproductive System Neoplasm
CI-CAN-00001107Explore in graph →
Non-malignant1,533 active trials27 approved drugs58 evidence items
- NCIt
- C3054
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001107Explore in graph →
Clinical trials
6,899 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00003232 | Combination Chemotherapy in Treating Pain in Hormone Refractory Metastatic Prostate Cancer | completed | Phase 3 | 227 | NCIC Clinical Trials GroupNETWORK | 1 | Apr 3, 2020 | clinicaltrials |
| NCT00064194 | Vitamin E, Selenium, and Soy Protein in Preventing Cancer in Patients With High-Grade Prostate Neoplasia | completed | Phase 3 | 310 | NCIC Clinical Trials GroupNETWORK | 1 | Apr 3, 2020 | clinicaltrials |
| NCT02091661 | Radical Retropubic Prostatectomy Versus Conventional External Beam Radiotherapy for Clinically Localized Prostate Cancer | suspended | Phase 3 | 500 | University of Rome Tor VergataOTHER | 0 | Mar 25, 2020 | clinicaltrials |
| NCT01212991 | A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer(PREVAIL) | completed | Phase 3 | 1,717 | PfizerINDUSTRY | 22 | Mar 17, 2020 | clinicaltrials |
| NCT02991209 | Study of Testosterone vs Placebo in Testicular Cancer Survivors(Einstein) | completed | Phase 2 / Phase 3 | 69 | Mikkel BandakOTHER | 1 | Mar 6, 2020 | clinicaltrials |
| NCT00007644 | Prostate Cancer Intervention Versus Observation Trial (PIVOT)(PIVOT) | completed | Phase 3 | 731 | VA Office of Research and DevelopmentFED | 1 | Feb 24, 2020 | clinicaltrials |
| NCT02928692 | Minocycline Attenuate Postoperative Cognitive Dysfunction and Delirium(MAPOCD) | unknown | Phase 3 | 750 | RenJi HospitalOTHER | 1 | Jan 28, 2020 | clinicaltrials |
| NCT01591122 | Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer | completed | Phase 3 | 313 | Janssen Research & Development, LLCINDUSTRY | 4 | Jan 21, 2020 | clinicaltrials |
| NCT02260817 | Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer | completed | Phase 3 | 109 | Global Isotopes, LLC d/b/a Zevacor MolecularINDUSTRY | 1 | Dec 17, 2019 | clinicaltrials |
| NCT01902823 | Effect of Cancer Nurse Navigators on Patient Outcomes | terminated | Phase 2 / Phase 3 | 16 | University of Wisconsin, MadisonOTHER | 1 | Dec 13, 2019 | clinicaltrials |
| NCT01715129 | Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer(DKP 3M SC) | completed | Phase 3 | 126 | IpsenINDUSTRY | 5 | Dec 9, 2019 | clinicaltrials |
| NCT02918357 | Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence(PSMA BCR) | completed | Phase 2 / Phase 3 | 385 | University of California, San FranciscoOTHER | 1 | Dec 2, 2019 | clinicaltrials |
| NCT00415246 | Study to Evaluate a Subcutaneous Four Months Sustained-release Formulation of Triptorelin in Patients With Prostate Cancer | terminated | Phase 3 | 100 | IpsenINDUSTRY | 8 | Nov 22, 2019 | clinicaltrials |
| NCT01313273 | Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients(POSEIDON) | terminated | Phase 3 | 3 | IpsenINDUSTRY | 1 | Nov 22, 2019 | clinicaltrials |
| NCT02578940 | Fluciclovine (18F) PET/CT in biochemicAL reCurrence Of Prostate caNcer(FALCON) | completed | Phase 3 | 104 | Blue Earth DiagnosticsINDUSTRY | 1 | Oct 7, 2019 | clinicaltrials |
| NCT01305200 | Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant | completed | Phase 3 | 226 | Children's Oncology GroupNETWORK | 3 | Sep 17, 2019 | clinicaltrials |
| NCT02759783 | Conventional Care Versus Radioablation (Stereotactic Body Radiotherapy) for Extracranial Oligometastases(CORE) | unknown | Phase 2 / Phase 3 | 245 | Royal Marsden NHS Foundation TrustOTHER | 2 | Aug 21, 2019 | clinicaltrials |
| NCT04056754 | Study of Abiraterone Acetate in Subjects With Metastatic Castration Resistant Prostate Cancer | completed | Phase 3 | 268 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Aug 14, 2019 | clinicaltrials |
| NCT01695135 | A Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy | completed | Phase 3 | 214 | Janssen Research & Development, LLCINDUSTRY | 1 | Jul 18, 2019 | clinicaltrials |
| NCT01310894 | Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance.(PCM301) | completed | Phase 3 | 413 | Steba Biotech S.A.OTHER | 10 | Jul 11, 2019 | clinicaltrials |
| NCT01006395 | Prevention of Micro-architectural Bone Decay in Males With Non-metastatic Prostate Cancer Receiving Androgen Deprivation Therapy (ADT) | completed | Phase 2 / Phase 3 | 64 | Austin HealthOTHER_GOV | 1 | Jul 5, 2019 | clinicaltrials |
| NCT02085252 | A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer | completed | Phase 3 | 116 | TakedaINDUSTRY | 1 | Jun 28, 2019 | clinicaltrials |
| NCT00255125 | Role of Soy Supplementation in Prostate Cancer Development | completed | Phase 3 | 86 | VA Office of Research and DevelopmentFED | 1 | Jun 18, 2019 | clinicaltrials |
| NCT01308567 | Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer(FIRSTANA) | completed | Phase 3 | 1,168 | SanofiINDUSTRY | 25 | Jun 5, 2019 | clinicaltrials |
| NCT01707966 | Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer and Non-progressive Disease After First-line Docetaxel Therapy | completed | Phase 3 | 47 | Swiss Cancer InstituteOTHER | 1 | May 15, 2019 | clinicaltrials |
| NCT02615067 | Study to Evaluate 99mTc-MIP-1404 SPECT/CT Imaging in Men With Biopsy Proven Low-Grade Prostate Cancer(proSPECT-AS) | completed | Phase 3 | 531 | Molecular Insight Pharmaceuticals, Inc.INDUSTRY | 2 | Apr 10, 2019 | clinicaltrials |
| NCT02712320 | Open-Label Safety Extension Study in Patients Who Have Previously Participated and Have Benefited From LMIS 50 mg | completed | Phase 3 | 30 | Foresee Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Mar 26, 2019 | clinicaltrials |
| NCT02234115 | Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma | completed | Phase 3 | 137 | Foresee Pharmaceuticals Co., Ltd.INDUSTRY | 8 | Mar 5, 2019 | clinicaltrials |
| NCT01020448 | Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer(Triptocare) | completed | Phase 3 | 339 | IpsenINDUSTRY | 10 | Jan 30, 2019 | clinicaltrials |
| NCT02680041 | 18F Fluciclovine (FACBC) PET/CT in Patients With Rising PSA After Initial Prostate Cancer Treatment(LOCATE) | completed | Phase 3 | 221 | Blue Earth DiagnosticsINDUSTRY | 1 | Jan 28, 2019 | clinicaltrials |
| NCT00544076 | ED Recovery in Men Age </=65 Treated With Bilateral Nerve Sparing Robotic Assisted Prostatectomy for Prostate Cancer | terminated | Phase 3 | 110 | City of Hope Medical CenterOTHER | 1 | Jan 2, 2019 | clinicaltrials |
| NCT01193257 | Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castration-Resistant Prostate Cancer. | completed | Phase 3 | 1,099 | Millennium Pharmaceuticals, Inc.INDUSTRY | 14 | Dec 19, 2018 | clinicaltrials |
| NCT00974311 | Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy(AFFIRM) | completed | Phase 3 | 1,199 | PfizerINDUSTRY | 15 | Dec 11, 2018 | clinicaltrials |
| NCT02551341 | Lung Protective Ventilation During Robotic Assisted Prostatectomy | completed | Phase 3 | 24 | Jørgen Bjerggaard JensenOTHER | 1 | Nov 16, 2018 | clinicaltrials |
| NCT00002855 | Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer | completed | Phase 3 | 306 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT00838201 | Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer | completed | Phase 3 | 384 | AmgenINDUSTRY | 6 | Oct 18, 2018 | clinicaltrials |
| NCT00089674 | AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer | completed | Phase 3 | 1,468 | AmgenINDUSTRY | 0 | Oct 17, 2018 | clinicaltrials |
| NCT01810770 | Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis | completed | Phase 3 | 243 | BayerINDUSTRY | 4 | Sep 19, 2018 | clinicaltrials |
| NCT02840552 | The Safety and Efficacy of 18F-Fluoromethylcholine (18F-FCH) PET/CT in Prostate Cancer | completed | Phase 3 | 60 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | Aug 9, 2018 | clinicaltrials |
| NCT03623425 | Comparison of PET With 68GA-PSMA-11 and 18F-Fluorocholine for Recurrence in Men With Prostate Cancer(TEPGALCHOL) | unknown | Phase 3 | 46 | Central Hospital, Nancy, FranceOTHER | 1 | Aug 9, 2018 | clinicaltrials |
| NCT02053311 | Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents | withdrawn | Phase 3 | 0 | Swiss Cancer InstituteOTHER | 1 | Jul 30, 2018 | clinicaltrials |
| NCT03580239 | Everolimus in Castrated Resistant Prostate Cancer(CRPC)Patients With PI3K-AKT-mTOR Signaling Pathway Deficiency | unknown | Phase 3 | 120 | Tianjin Medical University Second HospitalOTHER | 1 | Jul 9, 2018 | clinicaltrials |
| NCT00132301 | Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma(CAP) | completed | Phase 3 | 298 | VA Office of Research and DevelopmentFED | 2 | Jun 25, 2018 | clinicaltrials |
| NCT00002597 | Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer | completed | Phase 3 | 2,028 | Radiation Therapy Oncology GroupNETWORK | 2 | Jun 14, 2018 | clinicaltrials |
| NCT01522443 | Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer(COMET-2) | terminated | Phase 3 | 119 | ExelixisINDUSTRY | 5 | May 23, 2018 | clinicaltrials |
| NCT00004635 | Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer | completed | Phase 3 | 159 | National Cancer Institute (NCI)NIH | 1 | May 22, 2018 | clinicaltrials |
| NCT00423475 | Radiation Therapy With or Without Goserelin in Treating Patients Who Have Undergone Surgery for Recurrent or Refractory Prostate Cancer | completed | Phase 3 | 743 | UNICANCEROTHER | 1 | May 17, 2018 | clinicaltrials |
| NCT02380027 | PRostate Evaluation for Clinically Important Disease: Sampling Using Image-guidance Or Not?(PRECISION) | completed | Phase 3 | 500 | University College, LondonOTHER | 1 | May 1, 2018 | clinicaltrials |
| NCT00988208 | Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer(Mainsail) | completed | Phase 3 | 1,059 | CelgeneINDUSTRY | 21 | Apr 4, 2018 | clinicaltrials |
| NCT01605227 | Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100(COMET-1) | completed | Phase 3 | 1,028 | ExelixisINDUSTRY | 14 | Mar 14, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Apr 3, 2020source: clinicaltrials